Kenvue (NYSE:KVUE) Releases FY24 Earnings Guidance

Kenvue (NYSE:KVUE) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $1.10-$1.20 for the period, compared to the consensus EPS estimate of $1.14. The company issued revenue guidance of $15.59-$15.90 billion, compared to the consensus revenue estimate of $15.63 billion.

Kenvue Stock Up 6.2 %

KVUE traded up $1.17 during trading hours on Tuesday, reaching $20.05. The company’s stock had a trading volume of 22,639,729 shares, compared to its average volume of 16,955,277. The company has a quick ratio of 0.78, a current ratio of 1.12 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average is $19.82 and its 200-day moving average is $20.11. Kenvue has a 52 week low of $17.82 and a 52 week high of $27.80.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.03. The company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm’s revenue was down 2.7% compared to the same quarter last year. Sell-side analysts forecast that Kenvue will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.99%. The ex-dividend date is Tuesday, May 7th.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their price target on Kenvue from $25.00 to $24.00 and set an overweight rating for the company in a report on Friday, February 9th. The Goldman Sachs Group started coverage on shares of Kenvue in a research report on Friday, March 1st. They issued a neutral rating and a $20.00 target price for the company. Sanford C. Bernstein assumed coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an underperform rating and a $18.00 price target on the stock. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a market perform rating for the company. Finally, Royal Bank of Canada lowered their target price on shares of Kenvue from $25.00 to $24.00 and set an outperform rating on the stock in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Hold and a consensus target price of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.